A Frog Skin Antimicrobial Peptide Reduces Atherosclerotic Plaque Formation by Suppressing Inflammation Through a Novel Molecular Pathway
The frog skin-derived antimicrobial peptide C-1b(3-13) significantly reduced atherosclerotic plaque formation and inflammation in mice by activating miR-590-5p, which suppressed the KLF12/p300/NF-kB inflammatory signaling cascade.
Quick Facts
What This Study Found
The antimicrobial peptide C-1b(3-13) from frog skin suppressed atherosclerosis through a specific molecular mechanism: it upregulated miR-590-5p, which directly targeted and inhibited KLF12 expression, reducing nuclear p300 accumulation and subsequently blocking NF-κB inflammatory signaling.
In ox-LDL-induced foam cells, miR-590-5p significantly suppressed pro-inflammatory cytokine secretion. In ApoE-/- atherosclerosis mice, C-1b(3-13) treatment markedly reduced aortic plaque formation, improved lipid metabolism, suppressed inflammatory responses, and shifted macrophage polarization (reducing pro-inflammatory CD68+ M1 macrophages within plaques). The full signaling axis was validated through miRNA sequencing, dual-luciferase reporter assays, and RNA immunoprecipitation.
Key Numbers
How They Did This
In vitro: miRNA sequencing identified miR-590-5p changes in ox-LDL-induced PMA-THP-1 foam cells treated with C-1b(3-13). Cytokine secretion was measured by ELISA. Target validation used dual-luciferase reporter and RIP-qPCR assays. Western blots assessed KLF12, p300, and NF-κB pathway proteins. In vivo: ApoE-/- mice (an established atherosclerosis model) were treated with C-1b(3-13). Plaque formation was assessed by Oil Red O and H&E staining of aortic roots. Macrophage distribution was analyzed by immunohistochemistry for CD68+ (M1) and CD206+ (M2) markers.
Why This Research Matters
Atherosclerosis is the underlying cause of most heart attacks and strokes, the leading causes of death worldwide. Current treatments primarily manage risk factors (cholesterol, blood pressure) rather than directly targeting plaque inflammation. Discovering that a natural antimicrobial peptide can suppress atherosclerotic inflammation through a previously unknown mechanism opens a new therapeutic avenue. The detailed molecular pathway (miR-590-5p → KLF12 → p300 → NF-κB) provides multiple potential drug targets.
The Bigger Picture
This study expands the therapeutic potential of antimicrobial peptides beyond their traditional role in fighting infections. Frog skin peptides are a rich source of bioactive compounds, and discovering anti-inflammatory and anti-atherosclerotic properties adds a cardiovascular dimension to this natural peptide library. The work also connects peptide biology to the burgeoning field of microRNA-based therapeutics, showing how a peptide can modulate gene regulation through microRNA pathways.
What This Study Doesn't Tell Us
This is entirely a preclinical study — cell culture and mouse model data that cannot be directly extrapolated to human atherosclerosis. ApoE-/- mice develop atherosclerosis differently than humans. The peptide's pharmacokinetics (absorption, stability, distribution) in humans are unknown. The study does not address potential off-target effects of systemic miR-590-5p upregulation. Dose-response relationships and optimal dosing schedules are not detailed in the abstract.
Questions This Raises
- ?Can the peptide C-1b(3-13) survive in human blood long enough to reach atherosclerotic plaques, or would a modified version be needed?
- ?Does long-term systemic upregulation of miR-590-5p have unintended effects on other tissues or biological processes?
- ?Could this peptide be combined with existing statin therapy to provide both cholesterol-lowering and anti-inflammatory plaque stabilization?
Trust & Context
- Key Stat:
- Markedly reduced plaque Aortic plaque formation was significantly decreased in atherosclerosis-prone mice treated with the frog skin antimicrobial peptide C-1b(3-13)
- Evidence Grade:
- This is a preclinical study combining in vitro mechanistic work with in vivo animal model validation. The molecular pathway is thoroughly characterized through multiple complementary techniques, but all evidence is pre-clinical with no human data.
- Study Age:
- Published in 2025, this is a recent study representing the cutting edge of repurposing natural antimicrobial peptides for cardiovascular applications.
- Original Title:
- The Frog Skin-Derived Antimicrobial Peptide Suppresses Atherosclerosis by Modulating the KLF12/p300 Axis Through miR-590-5p.
- Published In:
- International journal of molecular sciences, 26(23) (2025)
- Authors:
- Fan, Fan(2), Li, Meng-Miao, Qiu, Zhong-Peng, Li, Zhen-Jia, Shang, De-Jing
- Database ID:
- RPEP-10888
Evidence Hierarchy
Frequently Asked Questions
Why would a frog skin peptide work against heart disease?
Frog skin produces antimicrobial peptides to fight infections, but many of these peptides also have anti-inflammatory properties. Since atherosclerosis is fundamentally an inflammatory disease, this peptide's ability to suppress the NF-κB inflammatory pathway turned out to be beneficial for reducing arterial plaque formation in mice.
How does this peptide reduce plaque buildup?
The peptide activates a small regulatory RNA (miR-590-5p) in inflammatory cells. This RNA then blocks a chain of signals (KLF12 → p300 → NF-κB) that normally drive inflammation. With inflammation suppressed, fewer immune cells become foam cells (the building blocks of plaques), resulting in less plaque accumulation in artery walls.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10888APA
Fan, Fan; Li, Meng-Miao; Qiu, Zhong-Peng; Li, Zhen-Jia; Shang, De-Jing. (2025). The Frog Skin-Derived Antimicrobial Peptide Suppresses Atherosclerosis by Modulating the KLF12/p300 Axis Through miR-590-5p.. International journal of molecular sciences, 26(23). https://doi.org/10.3390/ijms262311497
MLA
Fan, Fan, et al. "The Frog Skin-Derived Antimicrobial Peptide Suppresses Atherosclerosis by Modulating the KLF12/p300 Axis Through miR-590-5p.." International journal of molecular sciences, 2025. https://doi.org/10.3390/ijms262311497
RethinkPeptides
RethinkPeptides Research Database. "The Frog Skin-Derived Antimicrobial Peptide Suppresses Ather..." RPEP-10888. Retrieved from https://rethinkpeptides.com/research/fan-2025-the-frog-skinderived-antimicrobial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.